CRISPR activation (CRISPRa) systems for the upregulation of endogenous genes involved in pancreatic beta-cell regeneration and insulin sensitivity: a novel approach for type 2 diabetes treatment

Insulin resistance and increasing pancreatic β-cell dysfunction are the hallmarks of type 2 diabetes (T2D), a chronic metabolic disease. The molecular mechanisms underlying β-cell failure and impaired insulin signalling are not directly addressed by current therapeutic approaches, which instead concentrate on glycaemic control and symptom management. A new conceptual framework for modifying endogenous gene expression without causing irreversible genomic changes is provided by emerging gene regulation technologies, especially CRISPR activation (CRISPRa). Targeted upregulation of genes involved in insulin sensitivity and β-cell regeneration, such as PDX1, MAFA, NGN3, IRS2 and FOXO1, which are important regulators of pancreatic function and glucose homeostasis, is made possible by CRISPRa. Improved metabolic regulation may result from the controlled activation of these genes, which may also help β-cell functional recovery and improve insulin signalling pathways. CRISPRa-based gene activation techniques may provide long-term therapeutic potential as part of future precision medicine approaches for T2D management, even though this strategy is still theoretical and needs substantial experimental validation. The conceptual framework, biological justification, possible uses and major technical and translational difficulties related to CRISPRa-based interventions in T2D are covered in this article.